Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1 247.5
1 948.7
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Sun Pharmaceutical Industries Ltd
Sun Pharmaceutical Industries Ltd
Net Issuance of Debt
Sun Pharmaceutical Industries Ltd
Net Issuance of Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Issuance of Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Net Issuance of Debt
₹4.5B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Net Issuance of Debt
₹32.7B
|
CAGR 3-Years
143%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Net Issuance of Debt
-₹5.7B
|
CAGR 3-Years
37%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Lupin Ltd
NSE:LUPIN
|
Net Issuance of Debt
-₹4.6B
|
CAGR 3-Years
25%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Net Issuance of Debt
-₹13.9B
|
CAGR 3-Years
-12%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Net Issuance of Debt
₹314.4m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Sun Pharmaceutical Industries Ltd
Glance View
Sun Pharmaceutical Industries Ltd. began its journey in 1983 with a vision to provide quality healthcare to billions worldwide. Originating from India, Sun Pharma has steadily emerged as a global leader in the pharmaceutical industry. The company’s strength stems from its ability to efficiently manufacture, develop, and market a wide range of generic pharmaceuticals and therapeutic formulations. With a significant footprint in over 100 countries, it is driven by a robust pipeline of drugs encompassing key therapeutic areas such as psychiatry, cardiology, neurology, and gastroenterology. A hallmark of Sun Pharma’s strategy has been its strong focus on research and development, specifically in creating affordable medicines that tackle complex medical conditions. The company’s business model revolves around a dual strategy: the development of complex generics and innovative specialty products. This approach allows Sun Pharma to capitalize on both the high-volume, cost-efficient production of off-patent drugs and the value-driven, specialized therapy segments. By leveraging its R&D capabilities, the company explores new drug delivery systems and complex formulations, which not only ensure a steady flow of new product introductions but also enhance its competitive edge in the market. This blend of innovation and scale positions Sun Pharmaceutical Industries Ltd. as a dynamic force in the global pharmaceutical landscape, continually navigating the intricate balance of providing both profitable growth and accessible healthcare solutions.
See Also
What is Sun Pharmaceutical Industries Ltd's Net Issuance of Debt?
Net Issuance of Debt
4.5B
INR
Based on the financial report for Sep 30, 2024, Sun Pharmaceutical Industries Ltd's Net Issuance of Debt amounts to 4.5B INR.
You don't have any saved screeners yet
